Satellos Bioscience
MSLESatellos Bioscience Inc. (TSXV: MSLE) is a publicly traded biotechnology company based in Canada. The company's primary business focus is the discovery and development of novel therapeutics designed to regenerate skeletal muscle. Its research is centered on addressing the root cause of muscle degeneration in various conditions, with a key therapeutic area being muscular dystrophies. The company’s scientific approach is based on its proprietary discovery that muscle stem cells, known as satellite cells, have a previously unrecognized defect in their polarity and spatial orientation during the regeneration process in dystrophic muscle. Satellos is advancing a small molecule drug development program aimed at correcting this polarity mechanism to restore the body's innate muscle regeneration. Its lead program is targeting Duchenne muscular dystrophy, a severe genetic disorder characterized by progressive muscle degeneration and weakness. As a clinical-stage entity, Satellos Bioscience operates through its research and development programs to translate its scientific findings into potential treatments. The company’s work falls within the sectors of biotechnology and regenerative medicine, with the objective of developing therapies for degenerative muscle conditions where current treatment options are limited.
MSLE · Stock Price
Historical price data
About
Satellos Bioscience Inc. (TSXV: MSLE) is a publicly traded biotechnology company based in Canada. The company's primary business focus is the discovery and development of novel therapeutics designed to regenerate skeletal muscle. Its research is centered on addressing the root cause of muscle degeneration in various conditions, with a key therapeutic area being muscular dystrophies. The company’s scientific approach is based on its proprietary discovery that muscle stem cells, known as satellite cells, have a previously unrecognized defect in their polarity and spatial orientation during the regeneration process in dystrophic muscle. Satellos is advancing a small molecule drug development program aimed at correcting this polarity mechanism to restore the body's innate muscle regeneration. Its lead program is targeting Duchenne muscular dystrophy, a severe genetic disorder characterized by progressive muscle degeneration and weakness. As a clinical-stage entity, Satellos Bioscience operates through its research and development programs to translate its scientific findings into potential treatments. The company’s work falls within the sectors of biotechnology and regenerative medicine, with the objective of developing therapies for degenerative muscle conditions where current treatment options are limited.